BTIG Research Forecasts Strong Price Appreciation for United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics (NASDAQ:UTHR) had its price target hoisted by stock analysts at BTIG Research from $728.00 to $768.00 in a report released on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. BTIG Research‘s price objective would indicate a potential upside of 27.37% from the company’s current price.

UTHR has been the topic of a number of other reports. JPMorgan Chase & Co. dropped their price target on shares of United Therapeutics from $710.00 to $695.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 28th. Weiss Ratings downgraded shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, August 27th. Morgan Stanley increased their price objective on shares of United Therapeutics from $515.00 to $566.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 7th. The Goldman Sachs Group reissued a “sell” rating and set a $368.00 target price on shares of United Therapeutics in a research report on Thursday, October 15th. Finally, Bank of America dropped their target price on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Thirteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $673.80.

United Therapeutics Stock Up 0.3%

NASDAQ:UTHR traded up $1.66 during trading hours on Wednesday, hitting $602.98. 419,894 shares of the company traded hands, compared to its average volume of 554,787. The firm’s 50-day simple moving average is $530.53 and its 200-day simple moving average is $531.77. United Therapeutics has a one year low of $432.53 and a one year high of $609.99. The company has a market cap of $25.86 billion, a PE ratio of 21.49, a PEG ratio of 4.32 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.01 by ($0.30). United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. The firm had revenue of $832.50 million during the quarter, compared to the consensus estimate of $781.14 million. During the same quarter in the previous year, the company earned $7.16 EPS. The business’s revenue was up 4.1% compared to the same quarter last year. As a group, equities research analysts expect that United Therapeutics will post 26.09 EPS for the current year.

United Therapeutics announced that its board has approved a share buyback program on Thursday, October 22nd that allows the company to buy back $2 billion in shares. This buyback authorization allows the biotechnology company to purchase up to 8.3% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s board believes its stock is undervalued.

Insider Buying and Selling at United Therapeutics

In related news, CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $526.96, for a total transaction of $5,006,120.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares in the company, valued at approximately $170,968,483.28. This represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last quarter, insiders have sold 401,528 shares of company stock valued at $211,631,836. 8.60% of the stock is currently owned by insiders.

Institutional Trading of United Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new stake in shares of United Therapeutics during the 2nd quarter worth approximately $2,868,735,000. Janus Henderson Group PLC raised its holdings in shares of United Therapeutics by 8.9% in the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock worth $514,016,000 after purchasing an additional 70,829 shares during the period. Jupiter Topco LLC purchased a new position in United Therapeutics in the second quarter valued at approximately $450,140,000. First Trust Advisors LP lifted its stake in United Therapeutics by 23.5% in the first quarter. First Trust Advisors LP now owns 270,578 shares of the biotechnology company’s stock valued at $160,447,000 after purchasing an additional 51,555 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new position in United Therapeutics in the second quarter valued at approximately $159,522,000. Institutional investors own 94.08% of the company’s stock.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Q3 revenue rose 4% year over year to $832.5 million, above Wall Street expectations of about $781 million. Q3 2026 financial results
• Positive Sentiment: United Therapeutics announced a buydown of the Pfizer royalty tied to ralinepag, a therapy for pulmonary arterial hypertension. Ending or reducing the royalty burden could improve the economics of the drug, though the reports provided no financial terms. Ralinepag royalty buydown
• Neutral Sentiment: The company’s $2 billion share-repurchase authorization, approved in October, may support per-share results over time, but it is not a new announcement in today’s news. United Therapeutics stock coverage
• Negative Sentiment: Q3 earnings were $5.71 per share, below analysts’ roughly $6.01 consensus and down from $7.16 a year earlier. The earnings miss and falling net income temper the strong revenue comparison. Q3 earnings miss
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares, about 2.84% of her direct holdings. The sale may add a modest negative signal, though it leaves her with a substantial stake. SEC insider transaction filing

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company’s portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.

The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.